SCHEMBL3010748

SCHEMBL3010748

Cc1ccc(-c2csc(N3CCN(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.55
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MAPT P10636 6/20 0.54
USP2 O75604 2/20 0.54
HSD17B10 Q99714 2/20 0.54
RECQL P46063 1/20 0.54
AR P10275 1/20 0.53
HTT P42858 2/20 0.52
GBA1 P04062 2/20 0.49
KDM4E B2RXH2 2/20 0.48
HSD11B1 P28845 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 2/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655559 0.95 POLB (0.51) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3010804 0.91 ALDH1A1 (0.59) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3016313 0.90 MAPT (0.57) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3017554 0.89 POLB (0.54) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3015353 0.88 ALDH1A1 (0.56) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3014880 0.88 ALDH1A1 (0.55) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3008043 0.88 ALDH1A1 (0.58) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3007870 0.88 POLB (0.58) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3001976 0.88 ALDH1A1 (0.62) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3018379 0.88 HTT (0.62) POLBALDH1A1SMN1; SMN2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885ALDH1A1 3510/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.